GUJTHEM vs RUBICON: Stock Comparison
RUBICON RESEARCH is the larger company by market capitalisation. GUJARAT THEMIS BIOSYN shows a lower P/E and a higher net margin, while RUBICON RESEARCH shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GUJTHEM leads 6; RUBICON leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GUJTHEM | RUBICON |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GUJTHEM | RUBICON |
|---|---|---|
| Live Price | ₹414.4 | ₹1,791.8 |
| Day Change | 0.44% | 1.42% |
| Volume | 85,859 | 1.17 L |
| 52-Week High | ₹479 | ₹1,899 |
| 52-Week Low | ₹225.05 | ₹570.75 |
| Distance from 52W High | -13.49% | -5.65% |
Valuation
| Metric | GUJTHEM | RUBICON |
|---|---|---|
| Market Cap | ₹4,548 Cr | ₹29,632 Cr |
| P/E Ratio | 91.85x | 102.12x |
| P/B Ratio | 15.55x | 22.84x |
| EPS | ₹1.02 | ₹4.99 |
| Book Value | ₹26.41 | ₹77.93 |
| Dividend Yield | 0% | 0.08% |
Growth
| Metric | GUJTHEM | RUBICON |
|---|---|---|
| Revenue Growth (TTM YoY) | 17.2% | 43.5% |
| EPS Growth (TTM YoY) | -9.1% | 96.6% |
| Qtr Sales Growth | 0% | -19.95% |
| Qtr Profit Growth | 0% | -2.75% |
Profitability & Leverage
| Metric | GUJTHEM | RUBICON |
|---|---|---|
| ROE | 16.22% | 19.14% |
| ROCE | 11.12% | 20.49% |
| Net Margin | 28.15% | 13.48% |
| Operating Margin | 39.22% | 20.68% |
| Debt to Equity | 0.56x | 0.2x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GUJTHEM | RUBICON |
|---|---|---|
| Promoter Holding | 70.86% | 23.93%▼ 0.04 pp |
| FII Holding | 1.77%▼ 0.03 pp | 7.52%▼ 0.02 pp |
| DII Holding | 1.18% | 9.43%▼ 0.59 pp |
| Public Holding | 26.19%▲ 0.03 pp | 23.3%▲ 0.72 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GUJARAT THEMIS BIOSYN and RUBICON RESEARCH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.